Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy

Last updated: April 14, 2025
Sponsor: Mylan Specialty, LP
Overall Status: Completed

Phase

3

Condition

Pain

Acute Pain

Treatment

MR-107A-02

Placebo

Tramadol

Clinical Study ID

NCT06215859
MR-107A-02-TFZ-3002
  • Ages > 18
  • All Genders

Study Summary

MR-107A-02 is being studied to investigate its efficacy and safety for treatment of acute pain after herniorrhaphy.

Eligibility Criteria

Inclusion

Main Inclusion Criteria:

  1. Requirement for unilateral open inguinal herniorrhaphy with mesh under generalanesthesia.

  2. Has an American Society of Anesthesiologists Physical Status of I, II, or III.

  3. Pain Intensity (PI) using NRS-R ≥4 at any given timepoint during the 5 hoursfollowing end of surgery in the eligibility assessment as well as in the baselineassessment (NRS-R and NRS-A) immediately pre-dosing.

  4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e.,none, mild, moderate, severe) during the 5 hours following end of surgery.

  5. Able to understand and complete the study requirements (including literacy, toenable diary and questionnaire completion), provide written informed consent, andagree to abide by the study protocol and its restrictions.

Exclusion

Main Exclusion Criteria:

  1. Previously dosed with this formulation of MR 107A 02.

  2. Had any prior inguinal hernia repair in the past 24 months.

  3. Has a planned concurrent surgical procedure (e.g., bilateral herniorrhaphy).

  4. Has a pre-existing concurrent acute or chronic painful physical/restrictivecondition expected to require analgesic treatment in the postoperative period forpain that is not strictly related to the herniorrhaphy, and which may confound thepostoperative assessments.

  5. Known hypersensitivity to aspirin, NSAIDs, or other medication used in the study.

  6. Body mass index (BMI) >40 kg/m2 at screening.

  7. Body weight of <43 kg (105.8 lbs) at screening.

  8. History of GI bleeding or peptic ulcer disease.

  9. Known active inflammatory bowel disease, e.g., Crohn's Disease or ulcerativecolitis.

  10. A history of bleeding disorders that may affect coagulation.

  11. Subjects with prior stroke or transient ischemic attack in the past 12 months priorto screening.

Study Design

Total Participants: 579
Treatment Group(s): 3
Primary Treatment: MR-107A-02
Phase: 3
Study Start date:
December 29, 2023
Estimated Completion Date:
March 12, 2025

Connect with a study center

  • Investigator site 210

    Sheffield, Alabama 35660
    United States

    Site Not Available

  • Investigator site 213

    Phoenix, Arizona 85053
    United States

    Site Not Available

  • Investigator site 202

    Anaheim, California 92801
    United States

    Site Not Available

  • Investigator site 222

    Bakersfield, California 93301
    United States

    Site Not Available

  • Investigator site 208

    Riverside, California 92501
    United States

    Site Not Available

  • Investigator site 211

    Miami, Florida 33014
    United States

    Site Not Available

  • Investigator site 206

    Tampa, Florida 33613
    United States

    Site Not Available

  • Investigator site 207

    Atlanta, Georgia 30331
    United States

    Site Not Available

  • Investigator site 209

    Naperville, Illinois 60540
    United States

    Site Not Available

  • Investigator site 205

    Wichita, Kansas 67214
    United States

    Site Not Available

  • Investigator site 212

    Bellaire, Texas 77401
    United States

    Site Not Available

  • Investigator site 215

    Carrollton, Texas 75006
    United States

    Site Not Available

  • Investigator site 204

    Houston, Texas 77008
    United States

    Site Not Available

  • Investigator site 216

    McAllen, Texas 78501
    United States

    Site Not Available

  • Investigator site 203

    San Antonio, Texas 78240
    United States

    Site Not Available

  • Investigator site 214

    San Antonio, Texas 78258
    United States

    Site Not Available

  • Investigator site 219

    San Antonio, Texas 78229
    United States

    Site Not Available

  • Investigator site 201

    Salt Lake City, Utah 84107
    United States

    Site Not Available

  • Investigator site 224

    Eau Claire, Wisconsin 54701
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.